{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:08:46Z","timestamp":1790878126688,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,8,2]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Atrial fibrillation (\n                      <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n                      ) and heart failure with reduced ejection fraction frequently coexist. The AATAC (Ablation versus Amiodarone for Treatment of persistent Atrial fibrillation in patients with Congestive heart failure and an implantable device) trial suggests that catheter ablation may benefit these patients. However, applicability to contemporary ambulatory cardiology practice is unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Using the outpatient National Cardiovascular Data Registry\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Practice Innovation and Clinical Excellence Registry, we identified participants meeting\n                      <jats:styled-content style=\"fixed-case\">AATAC<\/jats:styled-content>\n                      enrollment criteria between 2013 and 2014. Treatment with medications and procedures was assessed at registry inclusion. From 164\u00a0166 patients with\n                      <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n                      and heart failure, 8483 (7%) patients potentially met\n                      <jats:styled-content style=\"fixed-case\">AATAC<\/jats:styled-content>\n                      inclusion criteria. Eligible subjects, compared to\n                      <jats:styled-content style=\"fixed-case\">AATAC<\/jats:styled-content>\n                      trial participants, were older (mean age, 71.2\u00b111.4\u00a0years) and had greater comorbidity (coronary artery disease 79.2%, hypertension 82.4%, and diabetes mellitus 31.8%).\n                      <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n                      was predominantly paroxysmal (65.5%), rather than persistent\/permanent (16.7%) or new onset (17.8%), whereas all patients in the\n                      <jats:styled-content style=\"fixed-case\">AATAC<\/jats:styled-content>\n                      trial had persistent\n                      <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>\n                      . Commonly used atrioventricular\u2010nodal blocking agents were carvedilol (71.2%), digoxin (31.9%), and metoprolol (27.1%). Rhythm control with anti\u2010arrhythmic drugs was reported in 29.0% of\n                      <jats:styled-content style=\"fixed-case\">AATAC<\/jats:styled-content>\n                      eligible patients (predominantly amiodarone [24.6%]) and 9.3% had undergone catheter ablation. Patients who underwent ablation were more likely to be younger and have less comorbidities than those who did not.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Among the contemporary ambulatory AF\/heart failure with reduced ejection fraction population, treatment is predominantly rate control with few catheter ablations. Application of\n                      <jats:styled-content style=\"fixed-case\">AATAC<\/jats:styled-content>\n                      findings has the potential to markedly increase the use of catheter ablation in this population, although significant differences in clinical profiles might influence ablation outcomes in practice.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.116.005273","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T14:25:38Z","timestamp":1504275938000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Atrial Fibrillation in Heart Failure US Ambulatory Cardiology Practices and the Potential for Uptake of Catheter Ablation: An National Cardiovascular Data Registry (NCDR\n                    <sup>\u00ae<\/sup>\n                    ) Research to Practice (R2P) Project"],"prefix":"10.1161","volume":"6","author":[{"given":"Jehu S.","family":"Mathew","sequence":"first","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas N.","family":"Marzec","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Mid\u2010America Heart Institute, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Jones","sequence":"additional","affiliation":[{"name":"Mid\u2010America Heart Institute, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Varosy","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"},{"name":"VA Eastern Colorado Health Care System, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Masoudi","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Maddox","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Allen","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.2000.tb07045.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00806-8"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2000.01208.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000121736.16643.11"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021328"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021375"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708789"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.158931"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000040"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.019406"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.04.007"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.043"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.922061"},{"key":"e_1_3_3_15_2","first-page":"22","article-title":"Use of rate and rhythm control drugs in patients younger than 65\u00a0years with atrial fibrillation","volume":"7","author":"Allen LaPointe NM","year":"2014","unstructured":"Allen LaPointe NM, Lokhnygina Y, Rimmler J, Sanders GD, Peterson ED, Al\u2010Khatib SM. Use of rate and rhythm control drugs in patients younger than 65\u00a0years with atrial fibrillation. J Atr Fibrillation. 2014;7:22\u201330.","journal-title":"J Atr Fibrillation"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.06.009"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03230-X"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00332-2"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.2.476"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.02.101"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.537175"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.06.1169"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.116.005273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:52:42Z","timestamp":1715583162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.116.005273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8,2]]}},"alternative-id":["10.1161\/JAHA.116.005273"],"URL":"https:\/\/doi.org\/10.1161\/jaha.116.005273","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,2]]},"assertion":[{"value":"2017-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e005273"}}